



# Solid Tumor Pre-Infusion Data

**Registry Use Only**

Sequence Number:

Date Received:

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

Event date: \_\_\_\_\_ — \_\_\_\_\_ — \_\_\_\_\_  
                  YYYY                  MM                  DD

DRAFT

### Subsequent Infusion

If this is a report of a second or subsequent infusion for the same disease subtype and this baseline disease insert has not been completed for the previous infusion (e.g. recipient was on TED track for the prior infusion, prior infusion was autologous with no consent, prior infusion was not reported to the CIBMTR), select “No” and begin the form at question two.

1. Is this the report of a second or subsequent infusion for the same disease?

Yes - **Go to questions 27**

No - **Go to question 2**

### Disease Assessment at Diagnosis

2. Specify the solid tumor sub-disease (*ICD10 code*)

#### Malignant neoplasm of other connective and soft tissue

- Malignant neoplasm of connective and soft tissue of head, face and neck (C49.0)
- Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder (C49.10)
- Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder (C49.11)
- Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder (C49.12)
- Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip (C49.20)
- Malignant neoplasm of connective and soft tissue of right lower limb, including hip (C49.21)
- Malignant neoplasm of connective and soft tissue of left lower limb, including hip (C49.22)
- Malignant neoplasm of connective and soft tissue of thorax (C49.3)
- Malignant neoplasm of connective and soft tissue of abdomen (C49.4)
- Malignant neoplasm of connective and soft tissue of pelvis (C49.5)
- Malignant neoplasm of connective and soft tissue of trunk, unspecified (C49.6)
- Malignant neoplasm of overlapping sites of connective and soft tissue (C49.8)
- Malignant neoplasm of connective and soft tissue, unspecified (C49.9)

#### Malignant neoplasm of bone and articular cartilage of limbs

- Malignant neoplasm of scapula and long bones of unspecified upper limb (C40.00)
- Malignant neoplasm of scapula and long bones of right upper limb (C40.01)
- Malignant neoplasm of scapula and long bones of left upper limb (C40.02)
- Malignant neoplasm of short bones of unspecified upper limb (C40.10)
- Malignant neoplasm of short bones of right upper limb (C40.11)
- Malignant neoplasm of short bones of left upper limb (C40.12)
- Malignant neoplasm of long bones of unspecified lower limb (C40.20)
- Malignant neoplasm of long bones of right lower limb (C40.21)
- Malignant neoplasm of long bones of left lower limb (C40.22)

**Malignant neoplasm of bone and articular cartilage of other and unspecified sites**

- Malignant neoplasm of bones of skull and face (C41.0)
- Malignant neoplasm of mandible (C41.1)
- Malignant neoplasm of vertebral column (C41.2)
- Malignant neoplasm of ribs, sternum and clavicle (C41.3)
- Malignant neoplasm of pelvic bones, sacrum and coccyx (C41.4)
- Malignant neoplasm of short bones of unspecified lower limb (C40.30)
- Malignant neoplasm of short bones of right lower limb (C40.31)
- Malignant neoplasm of short bones of left lower limb (C40.32)
- Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb (C40.80)
- Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb (C40.81)
- Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb (C40.82)
- Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb (C40.90)
- Malignant neoplasm of unspecified bones and articular cartilage of right limb (C40.91)
- Malignant neoplasm of unspecified bones and articular cartilage of left limb (C40.92)

3. Two largest dimensions of target lesion: \_\_\_\_\_ x \_\_\_\_\_ cm

4. Were metastases present?

- Yes – **Go to question 5**
- No – **Go to question 7**

5. Location of metastases (*check all that apply*)

- Bone – **Go to question 7**
- Brain – **Go to question 7**
- Liver – **Go to question 7**
- Lung – **Go to question 7**
- Lymph nodes, distant – **Go to question 7**
- Lymph nodes, local / regional – **Go to question 7**
- Musculoskeletal – **Go to question 7**
- Other location – **Go to question 6**

6. Specify other location: \_\_\_\_\_

**Cytogenetic analysis**

7. Were cytogenetics tested? (*FISH or karyotyping*)

- Yes – **Go to question 8**
- No – **Go to question 18**

8. Were cytogenetics tested via FISH?

- Yes - **Go to question 9**
- No - **Go to question 13**

9. Results of tests

- Abnormalities identified – **Go to question 10**
- No abnormalities – **Go to question 13**

10. International System for Human Cytogenetic Nomenclature (ISCN) compatible string: \_\_\_\_\_

11. Specify cytogenetic abnormalities (*check all that apply*)

**Translocation**

- t(1;13), PAX7-FOXO1 – **Go to question 13**
- t(1;16), CBFβ-MYH11 – **Go to question 13**
- t(2;13), PAX3-FKHR – **Go to question 13**
- t(7;16), FUS/CREB3L2 – **Go to question 13**
- t(7;22), EWS-ETV1 – **Go to question 13**
- t(11;22), EWS/FLI – **Go to question 13**
- t(12;14), IGH-CCND1 – **Go to question 13**
- t(12;15), ETV6-NTRK3 – **Go to question 13**
- t(12;16), FUS-CHOP – **Go to question 13**
- t(12;19) – **Go to question 13**
- t(12;22), MN1-TEL – **Go to question 13**
- t(13;22) – **Go to question 13**
- t(17;22), PDGFB/COL1A1 – **Go to question 13**
- t(21;22), EWS/ERG – **Go to question 13**
- t(X;17) – **Go to question 13**
- t(X;18), SYT-SSX1 or SYT-SSX2 – **Go to question 13**

**Deletion**

- del(16q) / 16q- – **Go to question 13**
- del(17q) / 17q- – **Go to question 13**

**Insertion**

- ins(19p) / 19p+ – **Go to question 13**

**Other**

- Complex (>=3 distinct abnormalities) – **Go to question 13**
- Other abnormality – **Go to question 12**

12. Specify other abnormality: \_\_\_\_\_

13. Were cytogenetics tested via karyotyping?

- Yes – **Go to question 14**
- No – **Go to question 18**

14. Results of tests

- Abnormalities identified – **Go to question 15**
- No evaluable metaphases – **Go to question 18**
- No abnormalities – **Go to question 18**

15. International System for Human Cytogenetic Nomenclature (ISCN) compatible string: \_\_\_\_\_

16. Specify cytogenetic abnormalities (*check all that apply*)

**Translocation**

- t(1;13) – **Go to question 18**
- t(1;16) – **Go to question 18**
- t(2;13) – **Go to question 18**
- t(7;16) – **Go to question 18**
- t(7;22) – **Go to question 18**
- t(11;22) – **Go to question 18**
- t(12;14) – **Go to question 18**
- t(12;15) – **Go to question 18**
- t(12;16) – **Go to question 18**
- t(12;19) – **Go to question 18**
- t(12;22) – **Go to question 18**
- t(13;22) – **Go to question 18**
- t(17;22) – **Go to question 18**
- t(21;22) – **Go to question 18**
- t(X;17) – **Go to question 18**
- t(X;18) – **Go to question 18**

**Deletion**

- del(16q) / 16q- – **Go to question 18**
- del(17q) / 17q- – **Go to question 18**

**Insertion**

- ins(19p) / 19p+ – **Go to question 18**

CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

**Other**

- Complex (>=3 distinct abnormalities) – **Go to question 18**
- Other abnormality – **Go to question 17**

17. Specify other abnormality: \_\_\_\_\_

**CIBMTR strongly encourages attaching the cytogenetic analysis report.**

**Molecular markers**

18. Were tests for molecular markers performed? (*e.g., PCR, NGS*)

- Yes – **Go to question 19**
- No – **Go to question 23**

**Copy and complete questions 19-22 to report more than one gene mutation**

19. Specify the positive molecular marker

- SSX1 – **Go to question 21**
- SSX2 – **Go to question 21**
- SSX4B – **Go to question 21**
- Other molecular marker – **Go to question 20**
- None – **Go to question 23**

20. Specify other molecular marker: \_\_\_\_\_

21. Amino acid change

- Known – **Go to question 22**
- Unknown – **Go to question 23**

22. p. \_\_\_\_\_

**Copy and complete questions 19-22 to report more than one gene mutation**

**CIBMTR strongly encourages attaching the molecular marker report.**

23. Specify solid tumor grade / differentiation

- Grade I
- Grade II
- Grade III
- Grade IV
- Unknown

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

**Solid tumor TNM classification**

24. Solid tumor – (T) tumor

- TX
- T0
- T1a
- T1b
- T2a
- T2b
- T3a
- T3b
- T4a
- T4b
- Unknown

25. Solid tumor – (N) lymph node

- NX
- N0
- N1
- N1a
- N1b
- N1c
- N2
- N2a
- N2b
- N2c
- N3
- Unknown

26. Solid tumor – (M) metastasis

- M0
- M1
- M1a
- M1b
- M1c
- Unknown





CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

- Docetaxel – **Go to question 37**
- Doxorubicin (Adriamycin) – **Go to question 37**
- Etoposide (VP-16, VePesid) – **Go to question 37**
- Ifosfamide (Ifex) – **Go to question 37**
- Imatinib (Gleevec) – **Go to question 37**
- Melphalan (L-PAM, Alkeran) – **Go to question 37**
- Pazopanib - **Go to question 37**
- Sunitinib (Sutent, SU11248) – **Go to question 37**
- Topotecan (Hycamtin) – **Go to question 37**
- Trabectedin – **Go to question 37**
- Vincristine (VCR, Oncovin) – **Go to question 37**
- Other therapy – **Go to question 36**

36. Specify other therapy: \_\_\_\_\_

37. Did the recipient receive any targeted agent? *(prior to collection)*

- Yes – **Go to question 38**
- No – **Go to question 43**

38. Date therapy started: \_\_\_\_\_

YYYY                      MM                      DD

39. Is therapy ongoing?

- Yes – **Go to question 41**
- No – **Go to question 40**

40. Date therapy stopped: \_\_\_\_\_

YYYY                      MM                      DD

41. Specify targeted therapy *(check all that apply)*

- Catequentinib – **Go to question 43**
- Docetaxel – **Go to question 43**
- Eribulin – **Go to question 43**
- Gemcitabine – **Go to question 43**
- Olaratumab – **Go to question 43**
- Paclitaxel – **Go to question 43**
- Pazopanib – **Go to question 43**
- Regorafenib – **Go to question 43**



CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

48. Did the recipient receive any targeted agent as bridging therapy? (*between collection and infusion*)

Yes – **Go to question 49**

No – **Go to question 51**

49. Specify targeted therapy

Catequentinib – **Go to question 51**

Docetaxel – **Go to question 51**

Eribulin – **Go to question 51**

Gemcitabine – **Go to question 51**

Olaratumab – **Go to question 51**

Paclitaxel – **Go to question 51**

Pazopanib – **Go to question 51**

Regorafenib – **Go to question 51**

Trabectedin – **Go to question 51**

Other targeted therapy – **Go to question 50**

50. Specify other targeted therapy: \_\_\_\_\_

**Copy and complete questions 44 – 50 if there is more than one therapy**

51. Did the recipient undergo radiation? (*between collection and infusion*)

Yes

No

52. Did the recipient undergo surgery? (*between collection and infusion*)

Yes

No

**Total Cumulative Exposure to Systemic Therapy / Radiation Therapy**

53. Total number of lines of systemic therapy received: \_\_\_\_

54. Exposure to anthracycline agents (*check all that apply*)

Daunorubicin – **Go to question 55**

Doxorubicin – **Go to question 56**

Epirubicin – **Go to question 57**

Idarubicin – **Go to question 58**

Mitoxantrone – **Go to question 59**

Valrubicin – **Go to question 60**

CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

Other anthracycline – **Go to question 61**

None – **Go to question 63**

55. Total cumulative dose of daunorubicin: \_\_\_\_\_ mg/m<sup>2</sup>

56. Total cumulative dose of doxorubicin: \_\_\_\_\_ mg/m<sup>2</sup>

57. Total cumulative dose of epirubicin: \_\_\_\_\_ mg/m<sup>2</sup>

58. Total cumulative dose of idarubicin: \_\_\_\_\_ mg/m<sup>2</sup>

59. Total cumulative dose of mitoxantrone: \_\_\_\_\_ mg/m<sup>2</sup>

60. Total cumulative dose of valrubicin: \_\_\_\_\_ mg/m<sup>2</sup>

61. Specify other anthracycline: \_\_\_\_\_

62. Total cumulative dose of other anthracycline: \_\_\_\_\_ mg/m<sup>2</sup>

63. Exposure to alkylating agents (*check all that apply*)

Carboplatin – **Go to question 64**

Cisplatin – **Go to question 65**

Cyclophosphamide – **Go to question 66**

Ifosfamide – **Go to question 67**

Melphalan – **Go to question 68**

Oxaliplatin – **Go to question 69**

None – **Go to question 70**

64. Total cumulative dose of carboplatin: \_\_\_\_\_ mg/m<sup>2</sup>

65. Total cumulative dose of cisplatin: \_\_\_\_\_ mg/m<sup>2</sup>

66. Total cumulative dose of cyclophosphamide: \_\_\_\_\_ mg/m<sup>2</sup>

67. Total cumulative dose of ifosfamide: \_\_\_\_\_ mg/m<sup>2</sup>

68. Total cumulative dose of melphalan: \_\_\_\_\_ mg/m<sup>2</sup>

69. Total cumulative dose of oxaliplatin: \_\_\_\_\_ mg/m<sup>2</sup>

70. Exposure to targeted therapies (*check all that apply*)

Catequentinib – **Go to question 72**

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

- Docetaxel – **Go to question 72**
- Eribulin – **Go to question 72**
- Gemcitabine – **Go to question 72**
- Olaratumab – **Go to question 72**
- Paclitaxel – **Go to question 72**
- Pazopanib – **Go to question 72**
- Regorafenib – **Go to question 72**
- Trabectedin – **Go to question 72**
- Other targeted therapy – **Go to question 71**
- None – **Go to question 72**

71. Specify other targeted therapy: \_\_\_\_\_

### Radiation therapy

72. Radiation therapy

- Yes – **Go to question 73**
- No – **Go to question 78**

73. Local / regional

- Yes – **Go to question 74**
- No – **Go to question 75**

74. Total dose: \_\_\_\_\_ cGy

75. Non-primary

- Yes – **Go to question 76**
- No – **Go to question 78**

76. Non-primary site (*check all that apply*)

- Bone – **Go to question 78**
- Brain – **Go to question 78**
- Liver – **Go to question 78**
- Lung – **Go to question 78**
- Lymph nodes, distant – **Go to question 78**
- Musculoskeletal – **Go to question 78**
- Other non-primary site – **Go to question 77**

77. Specify other non-primary site: \_\_\_\_\_



87. Specify cytogenetic abnormalities (*check all that apply*)

**Translocation**

- t (1;13), PAX7-FOXO1 – **Go to question 89**
- t (1;16), CFBF-MYH11 – **Go to question 89**
- t (2;13), PAX3-FKHR – **Go to question 89**
- t (7;16), FUS/CREB3L2 – **Go to question 89**
- t (7;22), EWS-ETV1 – **Go to question 89**
- t (11;22), EWS/FLI – **Go to question 89**
- t (12;14), IGH-CCND1 – **Go to question 89**
- t (12;15), ETV6-NTRK3 – **Go to question 89**
- t (12;16), FUS-CHOP – **Go to question 89**
- t (12;19) – **Go to question 89**
- t (12;22), MN1-TEL – **Go to question 89**
- t (13;22) – **Go to question 89**
- t (17;22), PDGFB/COL1A1 – **Go to question 89**
- t (21;22), EWS/ERG – **Go to question 89**
- t (X;17) – **Go to question 89**
- t (X;18), SYT-SSX1 or SYT-SSX2 – **Go to question 89**

**Deletion**

- del(16q) / 16q- – **Go to question 89**
- del(17q) / 17q- – **Go to question 89**

**Insertion**

- ins(19p) / 19p+ – **Go to question 89**

**Other**

- Complex (>=3 distinct abnormalities) – **Go to question 89**
- Other abnormality – **Go to question 88**

88. Specify other abnormality: \_\_\_\_\_

89. Were cytogenetics tested via karyotyping?

- Yes – **Go to question 90**
- No – **Go to question 94**

90. Results of tests

- Abnormalities identified – **Go to question 91**
- No evaluable metaphases – **Go to question 94**

CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

No abnormalities – **Go to question 94**

91. International System for Human Cytogenetic Nomenclature (ISCN) compatible string:  
\_\_\_\_\_

92. Specify cytogenetic abnormalities (*check all that apply*)

**Translocation**

- t (1;13) – **Go to question 94**
- t (1;16) – **Go to question 94**
- t (2;13) – **Go to question 94**
- t (7;16) – **Go to question 94**
- t (7;22) – **Go to question 94**
- t (11;22) – **Go to question 94**
- t (12;14) – **Go to question 94**
- t (12;15) – **Go to question 94**
- t (12;16) – **Go to question 94**
- t (12;19) – **Go to question 94**
- t (12;22) – **Go to question 94**
- t (13;22) – **Go to question 94**
- t (17;22) – **Go to question 94**
- t (21;22) – **Go to question 94**
- t (X;17) – **Go to question 94**
- t (X;18) – **Go to question 94**

**Deletion**

- del(16q) / 16q- – **Go to question 94**
- del(17q) / 17q- – **Go to question 94**

**Insertion**

- ins(19p) / 19p+ – **Go to question 94**

**Other**

- Complex (>=3 distinct abnormalities) – **Go to question 94**
- Other abnormality – **Go to question 93**

93. Specify other abnormality: \_\_\_\_\_

**CIBMTR strongly encourages attaching the cytogenetic analysis report.**

**Molecular markers**



CIBMTR Center Number: \_\_\_\_\_ CIBMTR Research ID: \_\_\_\_\_

94. Were tests for molecular markers performed? (e.g. PCR, NGS)

- Yes – **Go to question 95**
- No – **Go to question 99**

**Copy and complete questions 95-98 to report more than one gene mutation**

95. Specify the positive molecular marker

- SSX1 – **Go to question 97**
- SSX2 – **Go to question 97**
- SSX4B – **Go to question 97**
- Other molecular marker – **Go to question 96**
- None – **Go to question 99**

96. Specify other molecular marker: \_\_\_\_\_

97. Amino acid change

- Known – **Go to question 98**
- Unknown – **Go to question 99**

98. p. \_\_\_\_\_

**Copy and complete questions 95-98 to report more than one gene mutation**

**CIBMTR strongly encourages attaching the molecular marker report.**

99. Specify solid tumor grade / differentiation

- Grade I
- Grade II
- Grade III
- Grade IV
- Unknown

**Solid tumor TNM classification**

100. Solid tumor - (T) tumor

- TX
- T0
- T1a
- T1b
- T2a

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

- T2b
- T3a
- T3b
- T4a
- T4b
- Unknown

101. Solid tumor - (N) lymph node

- NX
- N0
- N1
- N1a
- N1b
- N1c
- N2
- N2a
- N2b
- N2c
- N3
- Unknown

102. Solid tumor - (M) metastasis

- M0
- M1
- M1a
- M1b
- M1c
- Unknown